{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:33:10Z","timestamp":1724459590026},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00120-015-3989-7","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T16:04:49Z","timestamp":1446221089000},"page":"176-183","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lebensqualit\u00e4t von Patienten mit Prostatakarzinom unter Androgendeprivation mit GnRH-Analoga","Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues"],"prefix":"10.1007","volume":"55","author":[{"name":"TRIPTOSIX-Studiengruppe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Eisenhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Scheithe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Colling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,1]]},"reference":[{"key":"3989_CR1","unstructured":"Krebs in Deutschland 2009\/2010 (2013) Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.\u00a0V. RKI, Berlin"},{"key":"3989_CR2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1464-410X.2012.11198.x","volume":"111","author":"Kyrdalen","year":"2013","unstructured":"Kyrdalen AE, Dahl AA, Hernes E et al (2013) A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 111(2):221\u2013232","journal-title":"BJU Int"},{"key":"3989_CR3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.eururo.2011.11.053","volume":"61","author":"Boorjian","year":"2012","unstructured":"Boorjian SA, Eastham JA, Graefen M et al (2012) A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 61(4):664\u2013675","journal-title":"Eur Urol"},{"key":"3989_CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/1403494812467503","volume":"41","author":"Vanagas","year":"2013","unstructured":"Vanagas G, Mickeviciene A, Ulys A (2013) Does quality of life of prostate cancer patients differ by stage and treatment? Scand J Public Health 41(1):58\u201364","journal-title":"Scand J Public Health"},{"key":"3989_CR5","unstructured":"Glaeske G, Schicktanz C (2010) BARMER GEK Arzneimittel-Report 2010. In: BARMER GEK (Hrsg), St. Augustin"},{"key":"3989_CR6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39\u201346","journal-title":"J Natl Cancer Inst"},{"key":"3989_CR7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","volume":"302","author":"Nanda","year":"2009","unstructured":"Nanda A, Chen MH, Braccioforte MH et al (2009) Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302(8):866\u2013873","journal-title":"JAMA"},{"key":"3989_CR8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"Saigal","year":"2007","unstructured":"Saigal CS, Gore JL, Krupski TL et al (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110(7):1493\u20131500","journal-title":"Cancer"},{"key":"3989_CR9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/aja.2011.108","volume":"14","author":"Casey","year":"2012","unstructured":"Casey RG, Corcoran NM, Goldenberg SL (2012) Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl 14(2):226\u2013231","journal-title":"Asian J Androl"},{"key":"3989_CR10","first-page":"Doc13","volume":"2","author":"Rohde","year":"2006","unstructured":"Rohde V, Grabein K, Hessel F et al (2006) Orchiectomy versus medical therapy with LH-RH analogues for the treatment of advanced prostatic carcinoma. GMS Health Technol Assess 2:Doc13","journal-title":"GMS Health Technol Assess"},{"key":"3989_CR11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","volume":"65","author":"Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124\u2013137","journal-title":"Eur Urol"},{"key":"3989_CR12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1464-410X.2012.11611.x","volume":"111","author":"Pierorazio","year":"2013","unstructured":"Pierorazio PM, Walsh PC, Partin AW, Epstein JI et al (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111(5):753\u2013760","journal-title":"BJU Int"},{"key":"3989_CR13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"D","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969\u2013974","journal-title":"JAMA"},{"key":"3989_CR14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139\u2013144","journal-title":"J Clin Oncol"},{"key":"3989_CR15","unstructured":"Bokemeyer C, Markus B, Kollmannsberger C et al (2012) DGHO Leitlinie Prostatakarzinom. DGHO. http:\/\/www.dgho-onkopedia.de"},{"key":"3989_CR16","first-page":"37","volume":"7","author":"Kumar","year":"2005","unstructured":"Kumar RJ, Barqawi A, Crawford ED (2005) Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 7(Suppl 5):37\u201343","journal-title":"Rev Urol"},{"key":"3989_CR17","doi-asserted-by":"crossref","first-page":"e74149","DOI":"10.1371\/journal.pone.0074149","volume":"8","author":"Waldmann","year":"2013","unstructured":"Waldmann A, Schubert D, Katalinic A (2013) Normative data of the EORTC QLQ-C30 for the German population: a population-based survey. PLoS One 8(9):e74149","journal-title":"PLoS One"},{"key":"3989_CR18","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2004.07.089","volume":"22","author":"Collette","year":"2004","unstructured":"Collette L, van Andel G, Bottomley A et al (2004) Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol 22(19):3877\u20133885","journal-title":"J Clin Oncol"},{"key":"3989_CR19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s11136-006-0003-2","volume":"15","author":"Sullivan","year":"2006","unstructured":"Sullivan PW, JB Nelson, PM Mulani et al (2006) Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res 15(8):1297\u20131306","journal-title":"Qual Life Res"},{"key":"3989_CR20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2490-13-32","volume":"13","author":"Gupta","year":"2013","unstructured":"Gupta D, Braun DP, Staren ED (2013) Prognostic value of changes in quality of life scores in prostate cancer. BMC Urol 13(1):32","journal-title":"BMC Urol"},{"key":"3989_CR21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/13685538.2014.891013","volume":"17","author":"Lebret","year":"2014","unstructured":"Lebret T, Culine S, Davin JL et al (2014) Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study. Aging Male 17(2):87\u201393","journal-title":"Aging Male"},{"key":"3989_CR22","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/jnci\/92.21.1731","volume":"92","author":"Bayoumi","year":"2000","unstructured":"Bayoumi AM, Brown AD, Garber AM (2000) Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92(21):1731\u20131739","journal-title":"J Natl Cancer Inst"},{"key":"3989_CR23","first-page":"781","volume":"21","author":"Nyg\u00e5rd","year":"2001","unstructured":"Nyg\u00e5rd R, Norum J, Due J (2001) Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis. Anticancer Res 21(1B):781\u2013788","journal-title":"Anticancer Res"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-3989-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-015-3989-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-3989-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:04:39Z","timestamp":1558609479000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-015-3989-7"}},"subtitle":["Ergebnisse der nicht-interventionellen Studie TRIPTOSIX","Results of the noninterventional study TRIPTOSIX"],"short-title":[],"issued":{"date-parts":[[2015,11,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["3989"],"URL":"https:\/\/doi.org\/10.1007\/s00120-015-3989-7","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"type":"print","value":"0340-2592"},{"type":"electronic","value":"1433-0563"}],"subject":[],"published":{"date-parts":[[2015,11,1]]}}}